Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
91 studies found for:    MEK Inhibitor AZD-6244
Show Display Options
Rank Status Study
1 Completed A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244
Condition: Healthy Volunteers
Interventions: Drug: AZD6244 Dosing Period 1;   Drug: AZD6244 Dosing Period 2;   Drug: AZD6244 Dosing Period 3;   Drug: AZD6244 Dosing Period 4
2 Completed Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Condition: Thyroid Cancer
Intervention: Biological: AZD6244
3 Terminated
Has Results
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Recurrent Adult Diffuse Large Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
4 Completed
Has Results
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
5 Completed To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: selumetinib;   Drug: itraconazole;   Drug: fluconazole
6 Completed
Has Results
A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers
Condition: Healthy Volunteers Bioequivalence or Bioavailability Study
Intervention: Drug: selumetinib 75mg single dose
7 Completed To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: selumetinib;   Drug: rifampicin
8 Recruiting MEK Inhibitor and Thoracic Radiotherapy Trial
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AZD6244
9 Completed Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
Condition: Adult Solid Neoplasm
Interventions: Biological: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
10 Not yet recruiting Intermittent Selumetinib for Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: Selumetinib
11 Recruiting A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Conditions: Triple-Negative Breast Cancer;   Squamous Cell Lung Cancer;   Non-squamous Cell Lung Cancer With KRAS Mutations;   Non-squamous Cell Lung Cancer With Wild-type KRAS
Interventions: Drug: AZD2014;   Drug: AZD6244
12 Unknown  A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
13 Active, not recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Glioma;   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
14 Completed Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Recruiting Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Conditions: Recurrent Colorectal Carcinoma;   Solid Neoplasm;   Stage IIIA Colorectal Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIC Colorectal Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
16 Completed
Has Results
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
17 Recruiting Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Selumetinib
18 Active, not recruiting A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Conditions: Breast Cancer;   Breast Neoplasms;   Colon Cancer;   Colonic Cancer;   Colon Neoplasms;   Lung Cancer;   Melanoma;   Kidney Cancer
Interventions: Drug: AZD6244;   Drug: Dacarbazine;   Drug: Erlotinib;   Drug: Docetaxel;   Drug: Temsirolimus
19 Completed
Has Results
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
Conditions: Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib;   Drug: Temsirolimus
20 Completed To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Condition: Solid Tumours
Intervention: Drug: selumetinib (oral)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years